Immunization of mice by hollow mesoporous silica nanoparticles as carriers of porcine circovirus type 2 ORF2 protein.
BACKGROUND
Porcine circovirus type 2 (PCV2) is a primary etiological agent of post-weaning multi-systemic wasting syndrome (PMWS), which is a disease of increasing importance to the pig industry worldwide. Hollow mesoporous silica nanoparticles (HMSNs) have gained increasing interest for use in vaccines.


METHODS
To study the potential of HMSNs for use as a protein delivery system or vaccine carriers. HMSNs were synthesized by a sol-gel/emulsion(oil-in-water/ethanol) method, purified PCV2 GST-ORF2-E protein was loaded into HMSNs, and the resulting HMSN/protein mixture was injected into mice. The uptake and release profiles of protein by HMSNs in vitro were investigated. PCV2 GST-ORF2-E specific antibodies and secretion of IFN-γ were detected by enzyme-linked immunosorbent assays, spleen lymphocyte proliferation was measured by the MTS method, and the percentage of CD4+ and CD8+ were determined by flow cytometry.


RESULTS
HMSNs were found to yield better binding capacities and delivery profiles of proteins; the specific immune response induced by PCV2 GST-ORF2-E was maintained for a relatively long period of time after immunization with the HMSN/protein complex.


CONCLUSIONS
The findings suggest that HMSNs are good protein carriers and have high potential for use in future applications in therapeutic drug delivery.
State Key Laboratory of Veterinary Etiological Biology and National Foot and Mouth Disease Reference Laboratory, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Xujiaping1, Lanzhou, Gansu 730046, The People's Republic of China.
Hui-Chen
HC
Guo
Xiao-Ming
XM
Feng
Shi-Qi
SQ
Sun
Yan-Quan
YQ
Wei
De-Hui
DH
Sun
Xiang-Tao
XT
Liu
Zai-Xin
ZX
Liu
Jian-Xiong
JX
Luo
Hong
H
Yin
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D049109:Cell Proliferation; D017925:Circovirus / Q000276:immunology*; D004337:Drug Carriers / Q000008:administration & dosage*; D007371:Interferon-gamma / Q000378:metabolism; D051379:Mice; D053758:Nanoparticles / Q000008:administration & dosage*; D012822:Silicon Dioxide / Q000008:administration & dosage*; D013154:Spleen / Q000276:immunology; D014611:Vaccination / Q000379:methods*; D014764:Viral Proteins / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*
D000914:Antibodies, Viral; D004337:Drug Carriers; D014764:Viral Proteins; D014765:Viral Vaccines; D012822:Silicon Dioxide; D007371:Interferon-gamma